Consequences of Withholding Erythropoiesis-Stimulating Agents in Hospitalized Patients,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(08/2024)
Status: Approved
Intravenous Iron Treatment for Iron Deficiency in Heart Failure Patients: Assessing Clinical Outcome Improvement,
Role: PI,
LLU Dept. of Pharmacy Practice,
(06/2024)
Status: Approved
Assessing hypertension management and establishing targets in adult inpatients undergoing hemodialysis,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(05/2024)
Status: Approved
Comparison of Sodium Zirconium Cyclosilicate and Sodium Polystyrene Sulfonate in the Treatment of Acute Hyperkalemia,
Role: PI,
LLU Dept. of Pharmacy Practice,
(09/2023)
Status: Approved
A retrospective study determining the appropriate dosing of epoetin alfa for initiation and titration in patients with anemia of chronic kidney disease,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(10/2024)
Status: Approved
Outpatient Intravenous Furosemide for Patients with Heart Failure,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(10/2024)
Status: Approved
Safety of Intravenous Iron Supplementation in Iron-Deficient Patients with Acute Infection: A Retrospective Cohort Study,
Role: PI,
LLU Dept. of Pharmacy Practice,
(10/2025)
Status: Approved
Equity in Iron Therapy for Patients with Heart Failure with Reduced Ejection Fraction: Bridging the Gap Between Guidelines and Practice,
Role: PI,
LLU Dept. of Pharmacy Practice,
(07/2025)
Status: Approved